Please Download Flash to complete this viewing experience
You need to upgrade your Flash Player
Clinuvel
Clinuvel Pharmaceuticals Ltd (ASX: CUV; XETRA: UR9; ADR: CLVLY) is a leading and innovative Australian company focused on the development of Scenesse, its proprietary first-in-class photoprotective drug. Photoprotection is medical protection of the skin from UV and light. Clinuvel’s lead drug provides medical photoprotection.
Share Price & Announcements
Media Coverage
- Clinuvel adds to family
- Clinuvel seeks thriller repigmentation
- Clinuvel - Most interesting logos in Biopharma
- SurModics drug delivery tech has day in the sun with Clinuvel
- SurModics signs license agreement for UV treatment technology
- New drug may bring sufferers light relief
- Clinuvel Drug Offers Relief for Rare Light Sensitivity Malady, Study Shows
Sector News
- Drugmakers continue 'off-label marketing' despite large fines - NJ.com
- Spending on Drugs for Kids Rose 10.8% Last Year: Medco Report - WSJ Health Blog
- Budget 2010: A couple of little 'gems' but no major announcements for biotech - AusBiotech
- E&Y: 2009 forever changed the biopharma industry - Fierce Biotech
- The Drug Stock Sell-Off - Forbes.com